The incidence of prostate cancer （PCa） is rising steadily among males in many countries. Serum prostate-specific antigen （PSA） is widely applied to clinical diagnosis and screening of PCa. However, the so-called g...The incidence of prostate cancer （PCa） is rising steadily among males in many countries. Serum prostate-specific antigen （PSA） is widely applied to clinical diagnosis and screening of PCa. However, the so-called grey area of PSA levels 4.0-10.0 ng/mL has a low specificity of 25-40% resulting in a high rate of negative biopsy and overtreatment. So in order to treat PCa patients in early stage, there is an urgent need for new biomarkers in PCa diagnosis. The PCA3 gene, a non-coding RNA （ncRNA） that is highly expressed in prostate cancer （PCa） cells, has been identified as a molecular biomarkers to detect PCa, of which PCA3 has already under clinical application. PCA3 is strongly overexpressed in malignant prostate tissue compared to benign or normal adjacent one. Newly, PCA3 is considered to be a promising biomarker in clinical diagnosis and targeted therapy. The diagnostic significance of PCA3, however, is awaiting further researches. Moreover, it has been demonstrated recently that TMPRSS2-ERG gene fusion is identified as the predominant genetic change in patients diagnosed with PCa. Recent study revealed that combination of the PC43 and TMPRSS2-ERG gene fusion test optimizes PCa detection compared with that of single biomarker, which would lead to a considerable reduction of the number of prostate biopsies. In this review, we focused on the potential use of PCA3 and TMPRSS2-ERG gene fusion detection in the diagnosis of PCa.展开更多
Aim： To investigate the existence of TMPRSS2：ERG fusion gene in circulating tumor cells （CTC） from prostate cancer patients and its potential in monitoring tumor metastasis. Methods- We analyzed the frequency of T...Aim： To investigate the existence of TMPRSS2：ERG fusion gene in circulating tumor cells （CTC） from prostate cancer patients and its potential in monitoring tumor metastasis. Methods- We analyzed the frequency of TMPRSS2： ERG and TMPRSS2：ETV1 transcripts in 27 prostate cancer biopsies from prostatectomies, and TMPRSS2：ERG transcripts in CTC isolated from 15 patients with advanced androgen independent disease using reverse transcription polymerase chain reaction （RT-PCR）. Fluorescence in situ hybridization （FISH） was applied to analyze the genomic truncation of ERG, which is the result of TMPRSS2：ERG fusion in 10 of the 15 CTC samples. Results： TMPRSS2： ERG transcripts were found in 44% of our samples, but we did not detect expression of TMPRSS2：ETV1. Using FISH analysis we detected chromosomal rearrangements affecting the ERG gene in 6 of 10 CTC samples, including 1 case with associated TMPRSS2：ERG fusion at the primary site. However, TMPRSS2：ERG transcripts were not detected in any of the 15 CTC samples, including the 10 cases analyzed by FISH. Conclusion： Although further study is required to address the association between TMPRSS2：ERG fusion and prostate cancer metastasis, detection of genomic truncation of the ERG gene by FISH analysis could be useful for monitoring the appearance of CTC and the potential for prostate cancer metastasis.展开更多
目的探讨E26(E-Twenty six,ETS)相关融合基因(ETS-related gene,ERG)在前列腺癌早期诊断与淋巴结转移预测中的应用价值。方法选择2010年5月至2016年5月深圳市宝安区中心医院收治的怀疑为前列腺癌而接受前列腺活检的67例患者为研究对象...目的探讨E26(E-Twenty six,ETS)相关融合基因(ETS-related gene,ERG)在前列腺癌早期诊断与淋巴结转移预测中的应用价值。方法选择2010年5月至2016年5月深圳市宝安区中心医院收治的怀疑为前列腺癌而接受前列腺活检的67例患者为研究对象。所有患者均进行ERG相关融合基因表达检测和组织病理学检查,分析影响前列腺癌发生以及淋巴结转移的危险因素。结果 67例患者中,59例患者经过组织病理学检查明确为前列腺癌,8例患者经过组织病理学检查明确为前列腺良性病变。从59例前列腺癌患者中随机抽取8例,与8例确诊为前列腺良性病变者共同测定ERG相关融合基因表达情况。其中,前列腺癌组ERG相关融合基因阳性表达率为75.0%,前列腺良性病变组ERG相关融合基因阳性表达率为25.0%,其差异具有统计学意义(P<0.05);单因素分析显示,患者年龄、前列腺特异性抗原(prostate cancer specific antigen,PSA)水平、PSA速率、ERG相关融合基因是导致前列腺癌发生的高危因素(P<0.05);多因素回归分析显示,PSA速率和ERG相关融合基因是导致前列腺癌发生的独立危险因素(P<0.05);59例前列腺癌患者均进行手术治疗,术中发现淋巴结转移27例,非淋巴结转移32例,前列腺癌淋巴结转移诊断的ERG相关融合基因畸变率阈值为2.6%,ERG相关融合基因诊断前列腺癌淋巴结转移的ROC曲线下面积为0.820,高于PSA的ROC曲线下面积0.718,ERG相关融合基因诊断前列腺癌淋巴结转移的效能显著优于PSA(P<0.05)。结论 ERG相关融合基因阳性表达可以作为前列腺癌发生的辅助评估工具,且对前列腺癌淋巴结转移具有预测价值。展开更多
基金supported by the following grants: National Natural Science Foundation of China No. 31571413, 31201037 (to Dr. Yu) and No. 81570180, 81072103 (to Dr. Wang) from the National Natural Science Foundation of China
文摘The incidence of prostate cancer （PCa） is rising steadily among males in many countries. Serum prostate-specific antigen （PSA） is widely applied to clinical diagnosis and screening of PCa. However, the so-called grey area of PSA levels 4.0-10.0 ng/mL has a low specificity of 25-40% resulting in a high rate of negative biopsy and overtreatment. So in order to treat PCa patients in early stage, there is an urgent need for new biomarkers in PCa diagnosis. The PCA3 gene, a non-coding RNA （ncRNA） that is highly expressed in prostate cancer （PCa） cells, has been identified as a molecular biomarkers to detect PCa, of which PCA3 has already under clinical application. PCA3 is strongly overexpressed in malignant prostate tissue compared to benign or normal adjacent one. Newly, PCA3 is considered to be a promising biomarker in clinical diagnosis and targeted therapy. The diagnostic significance of PCA3, however, is awaiting further researches. Moreover, it has been demonstrated recently that TMPRSS2-ERG gene fusion is identified as the predominant genetic change in patients diagnosed with PCa. Recent study revealed that combination of the PC43 and TMPRSS2-ERG gene fusion test optimizes PCa detection compared with that of single biomarker, which would lead to a considerable reduction of the number of prostate biopsies. In this review, we focused on the potential use of PCA3 and TMPRSS2-ERG gene fusion detection in the diagnosis of PCa.
文摘Aim： To investigate the existence of TMPRSS2：ERG fusion gene in circulating tumor cells （CTC） from prostate cancer patients and its potential in monitoring tumor metastasis. Methods- We analyzed the frequency of TMPRSS2： ERG and TMPRSS2：ETV1 transcripts in 27 prostate cancer biopsies from prostatectomies, and TMPRSS2：ERG transcripts in CTC isolated from 15 patients with advanced androgen independent disease using reverse transcription polymerase chain reaction （RT-PCR）. Fluorescence in situ hybridization （FISH） was applied to analyze the genomic truncation of ERG, which is the result of TMPRSS2：ERG fusion in 10 of the 15 CTC samples. Results： TMPRSS2： ERG transcripts were found in 44% of our samples, but we did not detect expression of TMPRSS2：ETV1. Using FISH analysis we detected chromosomal rearrangements affecting the ERG gene in 6 of 10 CTC samples, including 1 case with associated TMPRSS2：ERG fusion at the primary site. However, TMPRSS2：ERG transcripts were not detected in any of the 15 CTC samples, including the 10 cases analyzed by FISH. Conclusion： Although further study is required to address the association between TMPRSS2：ERG fusion and prostate cancer metastasis, detection of genomic truncation of the ERG gene by FISH analysis could be useful for monitoring the appearance of CTC and the potential for prostate cancer metastasis.
文摘目的探讨E26(E-Twenty six,ETS)相关融合基因(ETS-related gene,ERG)在前列腺癌早期诊断与淋巴结转移预测中的应用价值。方法选择2010年5月至2016年5月深圳市宝安区中心医院收治的怀疑为前列腺癌而接受前列腺活检的67例患者为研究对象。所有患者均进行ERG相关融合基因表达检测和组织病理学检查,分析影响前列腺癌发生以及淋巴结转移的危险因素。结果 67例患者中,59例患者经过组织病理学检查明确为前列腺癌,8例患者经过组织病理学检查明确为前列腺良性病变。从59例前列腺癌患者中随机抽取8例,与8例确诊为前列腺良性病变者共同测定ERG相关融合基因表达情况。其中,前列腺癌组ERG相关融合基因阳性表达率为75.0%,前列腺良性病变组ERG相关融合基因阳性表达率为25.0%,其差异具有统计学意义(P<0.05);单因素分析显示,患者年龄、前列腺特异性抗原(prostate cancer specific antigen,PSA)水平、PSA速率、ERG相关融合基因是导致前列腺癌发生的高危因素(P<0.05);多因素回归分析显示,PSA速率和ERG相关融合基因是导致前列腺癌发生的独立危险因素(P<0.05);59例前列腺癌患者均进行手术治疗,术中发现淋巴结转移27例,非淋巴结转移32例,前列腺癌淋巴结转移诊断的ERG相关融合基因畸变率阈值为2.6%,ERG相关融合基因诊断前列腺癌淋巴结转移的ROC曲线下面积为0.820,高于PSA的ROC曲线下面积0.718,ERG相关融合基因诊断前列腺癌淋巴结转移的效能显著优于PSA(P<0.05)。结论 ERG相关融合基因阳性表达可以作为前列腺癌发生的辅助评估工具,且对前列腺癌淋巴结转移具有预测价值。
